{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:22:41Z","timestamp":1790738561652,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Vaccination and the use of neuraminidase inhibitors (NAIs) are currently the front lines of defense against seasonal influenza. The activity of influenza vaccines and antivirals drugs such as the NAIs can be affected by mutations in the influenza hemagglutinin (HA) protein. Numerous HA substitutions have been identified in nonclinical NAI resistance-selection experiments as well as in clinical specimens from NAI treatment or surveillance studies. These mutations are listed in the prescribing information (package inserts) for FDA-approved NAIs, including oseltamivir, zanamivir, and peramivir.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>NAI treatment-emergent H1 HA mutations were mapped onto the H1N1 HA1 trimeric crystal structure and most of them localized to the HA antigenic sites predicted to be important for anti-influenza immunity. Recombinant A\/California\/04\/09 (H1N1)-like viruses carrying HA V152I, G155E, S162\u2009N, S183P, and D222G mutations were generated. We then evaluated the impact of these mutations on the immune reactivity and replication potential of the recombinant viruses in a human respiratory epithelial cell line, Calu\u2212\u20093.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We found that the G155E and D222G mutations significantly increased viral titers ~\u200913-fold compared to the wild-type virus. The hemagglutination and microneutralization activity of goat and ferret antisera, monoclonal antibodies, and human serum samples raised against pandemic A(H1N1)pdm09 viruses was ~\u2009100-fold lower against mutants carrying G155E or D222G compared to the wild-type virus.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Although the mechanism by which HA mutations emerge during NAI treatment is uncertain, some NAI treatment-emergent HA mutations correlate with decreased immunity to influenza virus.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12985-019-1258-x","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T17:02:44Z","timestamp":1575046964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-0472","authenticated-orcid":false,"given":"Natalia A.","family":"Ilyushina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi E.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian J.","family":"O\u2019Rear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-5276","authenticated-orcid":false,"given":"Raymond P.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"issue":"1","key":"1258_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/irv.12486","volume":"12","author":"MA Rolfes","year":"2018","unstructured":"Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, et al. Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness. Influenza Other Respir Viruses. 2018;12(1):132\u20137.","journal-title":"Influenza Other Respir Viruses"},{"issue":"2Pt1","key":"1258_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0092-8674(82)90135-0","volume":"31","author":"AJ Caton","year":"1982","unstructured":"Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A\/PR\/8\/34 hemagglutinin (H1 subtype). Cell. 1982;31(2Pt1):417\u201327.","journal-title":"Cell"},{"issue":"5953","key":"1258_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.1178258","volume":"326","author":"SE Hensley","year":"2009","unstructured":"Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, Jayaraman A, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science. 2009;326(5953):734\u20136.","journal-title":"Science."},{"issue":"6161","key":"1258_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1126\/science.1244730","volume":"342","author":"BF Koel","year":"2013","unstructured":"Koel BF, Burke DF, Bestebroer TM, van der Vilet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976\u20139.","journal-title":"Science."},{"issue":"1","key":"1258_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0166-3542(00)00103-0","volume":"47","author":"JL McKimm-Breschkin","year":"2000","unstructured":"McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors \u2013 a review. Antivir Res. 2000;47(1):1\u201317.","journal-title":"Antivir Res"},{"issue":"1","key":"1258_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1128\/AAC.40.1.40","volume":"40","author":"JL McKimm-Breschkin","year":"1996","unstructured":"McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, et al. Generation and characterization of variants of NWS\/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother. 1996;40(1):40\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1258_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1006\/viro.1998.9194","volume":"246","author":"TJ Blick","year":"1998","unstructured":"Blick TJ, Sahasrabudhe A, McDonald M, Owens IJ, Morley PJ, Fenton RJ, et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology. 1998;246(1):95\u2013103.","journal-title":"Virology."},{"issue":"5","key":"1258_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1086\/314440","volume":"178","author":"LV Gubareva","year":"1998","unstructured":"Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178(5):1257\u201362.","journal-title":"J Infect Dis"},{"issue":"2","key":"1258_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2006.10.012","volume":"74","author":"M Baz","year":"2007","unstructured":"Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A\/H1N1 viruses selected in vitro with peramivir and zanamivir. Antivir Res. 2007;74(2):159\u201362.","journal-title":"Antivir Res"},{"issue":"8","key":"1258_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/jac\/dks150","volume":"67","author":"JL McKimm-Breschkin","year":"2012","unstructured":"McKimm-Breschkin JL, Rootes C, Mohr PG, Barrett S, Streltsov VA. In vitro passaging of a pandemic H1N1\/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. J Antimicrob Chemother. 2012;67(8):1874\u201383.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1258_CR11","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1093\/jac\/dkt205","volume":"68","author":"JL McKimm-Breschkin","year":"2013","unstructured":"McKimm-Breschkin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, et al. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother. 2013;68(10):2210\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"1258_CR12","unstructured":"Tamiflu (oseltamivir phosphate) tablet [package insert]. In: South San Francisco, CA. Roche Laboratories Inc. 1999 (approved). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021087s069,021246s052lbl.pdf."},{"key":"1258_CR13","unstructured":"Relenza (zanamivir) inhalation [package insert]. In: Research Triangle Park, NC. Glaxo Wellcome, Inc. 1999 (appoved). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021036s025lbl.pdf."},{"key":"1258_CR14","unstructured":"Rapivab (peramivir) injection [package insert]. In: Durham, NC. BioCryst Pharmaceuticals, Inc. 2014 (appoved). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/206426s004lbl.pdf."},{"issue":"2","key":"1258_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015190","volume":"6","author":"SE Hensley","year":"2011","unstructured":"Hensley SE, Das SR, Gibbs JS, Bailey AL, Schmidt LM, Bennink JR, et al. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS One. 2011;6(2):e15190.","journal-title":"PLoS One"},{"issue":"11","key":"1258_CR16","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1073\/pnas.100133697","volume":"97","author":"E Hoffmann","year":"2000","unstructured":"Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000;97(11):6108\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5976","key":"1258_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1126\/science.1186430","volume":"328","author":"R Xu","year":"2010","unstructured":"Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328(5976):357\u201360.","journal-title":"Science."},{"issue":"1","key":"1258_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jmv.23990","volume":"87","author":"A Melidou","year":"2015","unstructured":"Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Malisiovas N. Genetic analysis of post-pandemic 2010\u22122011 influenza A(H1N1)pdm09 hemagglutinin virus variants that caused mild, severe, and fatal infections in northern Greece. J Med Virol. 2015;87(1):57\u201367.","journal-title":"J Med Virol"},{"issue":"42","key":"1258_CR19","doi-asserted-by":"publisher","first-page":"19692","DOI":"10.2807\/ese.15.42.19692-en","volume":"15","author":"IG Barr","year":"2010","unstructured":"Barr IG, Cui L, Komadina N, Lee RT, Lin RT, Deng Y, et al. A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza seasoan in Australia, New Zealand and Singapore. Eurosurveillance. 2010;15(42):19692.","journal-title":"Eurosurveillance"},{"key":"1258_CR20","unstructured":"Tisdale M. Influenza M2 ion-channel and neuraminidase inhibitors. In: Mayers DL, Lerner SA, Ouellette M, Sobel JD, editors. (ed), Antimicrobial drug resistance: mechanisms of drug resistance. 2009;1:421\u2013447."},{"issue":"2","key":"1258_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","volume":"5","author":"FM Marty","year":"2017","unstructured":"Marty FM, Vidal-Puigserver J, Clark C, Gupta SK, Merino E, Garot D, et al. Intravenous zanamivir or oral oseltamivir for hospitalized patientns with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2017;5(2):135\u201346.","journal-title":"Lancet Respir Med"},{"key":"1258_CR22","unstructured":"A Study of intravenous zanamivir versus oral oseltamivir in adults and adolescents hospitalized with influenza (ZORO), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01231620."},{"key":"1258_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.antiviral.2016.08.023","volume":"134","author":"PJ Yates","year":"2016","unstructured":"Yates PJ, Raimonde DS, Zhao HH, Man CY, Steel HM, Mehta N, et al. Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects. Antivir Res. 2016;134:144\u201352.","journal-title":"Antivir Res"},{"key":"1258_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.meegid.2017.01.027","volume":"49","author":"N Korsun","year":"2017","unstructured":"Korsun N, Angelova S, Gregory V, Daniels R, Georgieva, McCauley J. Antigenic and genetic characterization of influenza viruses circulating in Bulgaria during the 2015\/2016 season. Infect Genet Evol. 2017;49:241\u201350.","journal-title":"Infect Genet Evol"},{"issue":"11","key":"1258_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112302","volume":"9","author":"DF Burke","year":"2014","unstructured":"Burke DF, Smith DJ. A recommended numbering scheme for influenza A HA subtypes. PLoS One. 2014;9(11):e112302.","journal-title":"PLoS One"},{"issue":"4","key":"1258_CR26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","volume":"37","author":"T Rowe","year":"1999","unstructured":"Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim X, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37(4):937\u201343.","journal-title":"J Clin Microbiol"},{"key":"1258_CR27","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.antiviral.2019.104539","volume":"169","author":"SE Adams","year":"2019","unstructured":"Adams SE, Lee N, Lugovtsev VY, Kan A, Donnelly RP, Ilyushina NA. Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors. Antivir Res. 2019;169:104539.","journal-title":"Antivir Res"},{"issue":"1","key":"1258_CR28","first-page":"1","volume":"60","author":"AE Fiore","year":"2011","unstructured":"Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2011;60(1):1\u201324.","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"1258_CR29","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669\u201379.","journal-title":"Gastroenterology."},{"issue":"9941","key":"1258_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST\u22121): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403\u201313.","journal-title":"Lancet."},{"issue":"3","key":"1258_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.chom.2013.02.008","volume":"13","author":"SR Das","year":"2013","unstructured":"Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, et al. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe. 2013;13(3):314\u201323.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"1258_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195525","volume":"13","author":"N Lee","year":"2018","unstructured":"Lee N, Khalenkov AM, Lugovtsev VY, Ireland DD, Samsonova AP, Bovin NV, et al. The use of plant lectins to regulate H1N1 influenza A virus receptor binding activity. PLoS One. 2018;13(4):e0195525.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"1258_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.virusres.2012.03.003","volume":"166","author":"I Rudneva","year":"2012","unstructured":"Rudneva I, Ignatieva A, Timofeeva T, Shilov A, Kushch A, Masalova O, et al. Escape mutants of pandemic influenza A\/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. Virus Res. 2012;166(1\u20132):61\u20137.","journal-title":"Virus Res"},{"issue":"1","key":"1258_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006796","volume":"14","author":"I Kosik","year":"2018","unstructured":"Kosik I, Ince WL, Gentles LE, Oler AJ, Kosikova M, Angel M, et al. Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs. PLoS Pathog. 2018;14(1):e1006796.","journal-title":"PLoS Pathog"},{"issue":"52","key":"1258_CR35","doi-asserted-by":"publisher","first-page":"21474","DOI":"10.1073\/pnas.1218841110","volume":"109","author":"YP Lin","year":"2012","unstructured":"Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A. 2012;109(52):21474\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1258_CR36","doi-asserted-by":"publisher","first-page":"e00120","DOI":"10.1128\/mBio.00120-12","volume":"3","author":"CD O\u2019Donnell","year":"2012","unstructured":"O\u2019Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, Li GM, et al. Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice. MBio. 2012;3(3):e00120\u201312.","journal-title":"MBio."},{"issue":"1","key":"1258_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(SICI)1099-1654(200001\/02)10:1<45::AID-RMV265>3.0.CO;2-R","volume":"10","author":"M Tisdale","year":"2000","unstructured":"Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol. 2000;10(1):45\u201355.","journal-title":"Rev Med Virol"},{"issue":"10","key":"1258_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001145","volume":"6","author":"J Ye","year":"2010","unstructured":"Ye J, Sorrell EM, Cai Y, Shao H, Xu K, Pena L, et al. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog. 2010;6(10):e1001145.","journal-title":"PLoS Pathog"},{"issue":"1","key":"1258_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008553","volume":"5","author":"M Igarashi","year":"2010","unstructured":"Igarashi M, Ito K, Yoshida R, Tomabechi D, Kida H, Takada A. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One. 2010;5(1):e8553.","journal-title":"PLoS One"},{"issue":"4","key":"1258_CR40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jcv.2011.01.013","volume":"50","author":"PK Chan","year":"2011","unstructured":"Chan PK, Lee N, Joynt GM, Choi KW, Cheung JL, Yeung AC, et al. Clinical and virological course of infection with haemagglutinin D222G mutant strain of 2009 pandemic influenza A (H1N1) virus. J Clin Virol. 2011;50(4):320\u20134.","journal-title":"J Clin Virol"},{"key":"1258_CR41","doi-asserted-by":"crossref","unstructured":"Kilander A, Rykkvin R, Dudman SG, Hungnes O. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009\u20132010. Euro Surveill. 2010;15(9).","DOI":"10.2807\/ese.15.09.19498-en"},{"issue":"22","key":"1258_CR42","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1128\/JVI.01136-10","volume":"84","author":"S Chutinimitkul","year":"2010","unstructured":"Chutinimitkul S, Herfst S, Steel J, Lowen AC, Ye J, van Riel D, et al. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol. 2010;84(22):11802\u201313.","journal-title":"J Virol"},{"issue":"9","key":"1258_CR43","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1007\/s00894-012-1423-2","volume":"18","author":"D Pan","year":"2012","unstructured":"Pan D, Xue W, Wang X, Guo J, Liu H, Yao X. Molecular mechanism of the enhanced virulence of 2009 pandemic influenza A(H1N1) virus from D222G mutation in the hemagglutinin: a molecular modeling study. J Mol Model. 2012;18(9):4355\u201366.","journal-title":"J Mol Model"},{"issue":"11","key":"1258_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001211","volume":"6","author":"SR Das","year":"2010","unstructured":"Das SR, Piugbo P, Hensley SE, Hurt DE, Bennink JR, Yewdell JW. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010;6(11):e1001211.","journal-title":"PLoS Pathog"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-019-1258-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:31:52Z","timestamp":1606523512000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-019-1258-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1186\/s12985-019-1258-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}